Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes

These data suggest BMF-219s potential as an oral, long-acting treatment for type 2 diabetes.